Detalhe da pesquisa
1.
The similarity of class II HLA genotypes defines patterns of autoreactivity in idiopathic bone marrow failure disorders.
Blood
; 138(26): 2781-2798, 2021 12 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-34748628
2.
Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia.
Blood
; 138(19): 1885-1895, 2021 11 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34075412
3.
Pharmacokinetics and pharmacodynamics of an oral formulation of decitabine and tetrahydrouridine.
Eur J Haematol
; 111(3): 345-355, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37417197
4.
Changing paradigms in oncology: Toward noncytotoxic treatments for advanced gliomas.
Int J Cancer
; 151(9): 1431-1446, 2022 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35603902
5.
OAS-RNase L innate immune pathway mediates the cytotoxicity of a DNA-demethylating drug.
Proc Natl Acad Sci U S A
; 116(11): 5071-5076, 2019 03 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30814222
6.
Extended experience with a non-cytotoxic DNMT1-targeting regimen of decitabine to treat myeloid malignancies.
Br J Haematol
; 188(6): 924-929, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31736067
7.
Low-Dose Azacitidine with DNMT1 Level Monitoring to Treat Post-Transplantation Acute Myelogenous Leukemia or Myelodysplastic Syndrome Relapse.
Biol Blood Marrow Transplant
; 25(6): 1122-1127, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30599207
8.
Targeting sickle cell disease root-cause pathophysiology with small molecules.
Haematologica
; 104(9): 1720-1730, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31399526
9.
ß-Hemoglobinopathies lead the way.
Blood
; 137(12): 1567-1569, 2021 03 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-33764430
10.
Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study.
PLoS Med
; 14(9): e1002382, 2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-28880867
11.
The LSD1 inhibitor RN-1 induces fetal hemoglobin synthesis and reduces disease pathology in sickle cell mice.
Blood
; 126(3): 386-96, 2015 Jul 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-26031919
12.
The LSD1 inhibitor RN-1 recapitulates the fetal pattern of hemoglobin synthesis in baboons (P. anubis).
Haematologica
; 101(6): 688-97, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-26858356
13.
Runx1 regulation of Pu.1 corepressor/coactivator exchange identifies specific molecular targets for leukemia differentiation therapy.
J Biol Chem
; 289(21): 14881-95, 2014 May 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-24695740
14.
Cytoplasmic dislocation of NPM1 and PU.1 in NPM1-mutated leukaemia is obscured by paraformaldehyde fixation.
Br J Haematol
; 189(3): 578-581, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32112392
15.
AML cells are differentially sensitive to chemotherapy treatment in a human xenograft model.
Blood
; 121(12): e90-7, 2013 Mar 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-23349390
16.
Mysteries of partial dihydroorotate dehydrogenase inhibition and leukemia terminal differentiation.
Haematologica
; 105(9): 2191-2193, 2020 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33054042
17.
Polycomb segment myeloid malignancies.
Blood
; 119(5): 1097-8, 2012 Feb 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-22308277
18.
Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine.
Blood
; 119(5): 1240-7, 2012 Feb 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-22160381
19.
SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes.
Blood
; 120(16): 3173-86, 2012 Oct 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-22826563
20.
Using PU.1 and Jun dimerization protein 2 transcription factor expression in myelodysplastic syndromes to predict treatment response and leukaemia transformation.
Ann Hematol
; 98(6): 1529-1531, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-30721335